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Abstract 
Background 
Fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA-FLS) contribute to 
joint inflammation and damage characteristic of the disease. RA-FLS express 
KCa1.1 (BK, Slo1, MaxiK, KCNMA1) as their major plasma membrane potassium 
channel. Blocking KCa1.1 reduces the invasive phenotype of RA-FLS and 
attenuates disease severity in animal models of RA. This channel has therefore 
emerged as a promising therapeutic target in RA. However, the pore-forming α 
subunit of KCa1.1 is widely distributed in the body, and blocking it induces severe 
side effects, thus limiting its value as a therapeutic target. On the other hand, 
KCa1.1 channels can also contain different accessory subunits with restricted tissue 
distribution that regulate channel kinetics and pharmacology. Identification of the 
regulatory subunits of KCa1.1 expressed by RA-FLS may therefore provide the 
opportunity for generating a selective target for RA treatment. 
Methods 
Highly invasive RA-FLS were isolated from patients with RA, and FLS from 
patients with osteoarthritis (OA) were used as minimally invasive controls. The β 
subunit expression by FLS was assessed by quantitative reverse transcription 
polymerase chain reactions, Western blotting, and patch-clamp electrophysiology 
combined with pharmacological agents. FLS were sorted by flow cytometry on the 
basis of their CD44 expression level for comparison of their invasiveness and with 
their expression of KCa1.1 α and β subunits. β1 and β3 subunit expression was 
reduced with small interfering RNA (siRNA) to assess their specific role in 
KCa1.1α expression and function and in FLS invasiveness. 
Results 
We identified functional β1 and β3b regulatory subunits in RA-FLS. KCa1.1 β3b 
subunits were expressed by 70 % of the cells and were associated with highly 
invasive CD44high RA-FLS, whereas minimally invasive CD44low RA-FLS and OA-
FLS expressed either β1 subunit. Furthermore, we found that silencing the β3 but 
not the β1 subunit with siRNA reduced KCa1.1 channel density at the plasma 
membrane of RA-FLS and inhibited RA-FLS invasiveness. 
Conclusions 
Our findings suggest the KCa1.1 channel composed of α and β3b subunits as an 
attractive target for the therapy of RA. 
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Background 
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that 
predominantly involves diarthrodial joints but can also target vital internal organs, 
including the heart and lungs [1, 2, 3]. In the last decades, management of RA has 
significantly improved with the development of new treatments; however, disease 
remission is rarely achieved, and most patients attain only mild to modest 
improvement [4]. Furthermore, current therapies significantly impair immune 
responses, rendering patients more susceptible to infections and cancer [5]. 
Therefore, novel therapeutic options that lead to pronounced improvement or 
remission without inducing immunosuppression are needed. 
Fibroblast-like synoviocytes (FLS) in RA (RA-FLS) have been implicated in 
disease pathogenesis, as they exhibit a transformed, “tumor-like” phenotype with 
increased invasiveness and production of proteases and of various proinflammatory 
and proangiogenic factors [6, 7, 8]. Importantly, the ex vivo invasiveness of FLS 
correlates with radiographic and histologic damage and therefore with disease 
severity [9, 10]. 
Highly invasive RA-FLS and FLS from arthritic rats express the functional 
calcium-activated potassium channel KCa1.1 (also known as BK, Slo1, MaxiK, 
or KCNMA1) as the major K+ channel at their plasma membrane [11, 12]. Blocking 
the function of KCa1.1 pore-forming α subunits in these FLS with paxilline inhibits 
their invasiveness and stops disease progression in animal models of RA [11, 12]. 
However, paxilline is a lipophilic small molecule that blocks all KCa1.1 channels 
found in major organs, regardless of channel subunit composition [13, 14, 15], and 
can cross cell membranes as well as the blood-brain barrier. It therefore induces 
severe side effects, such as tremors, incontinence, and hypertension [16, 17, 18]. 
Despite the drawbacks of the unspecific block of KCa1.1 by paxilline, the channel 
remains an attractive target for therapy because the regulatory subunits of KCa1.1 
have restricted tissue distribution and affect channel pharmacology [19, 20]. Four β 
subunits with distinct amino acid sequences have been described: β1 (KCNMB1, 
UniProt identifier Q16558), found in smooth muscles; β2 (KCNMB2, UniProt 
identifier Q9Y691), prevalent in the adrenal gland and brain; β3 (KCNMB3, 
UniProt identifier Q9NPA1), expressed mainly in the testis; and β4 (KCNMB4, 
UniProt identifier Q86W47), mostly expressed in the central nervous system 
[20, 21, 22, 23, 24, 25, 26]. The presence of β subunits affects the kinetics of the 
channel as well as the selectivity and affinity of various KCa1.1 channel 
modulators. Steroid compounds, such as lithocholic acid (LCA), selectively 
enhance KCa1.1 currents only if the channel contains the β1 subunit [27, 28]. In 
contrast, arachidonic acid (AA) amplifies currents in the presence of the β2 or β3 
subunit but not the β1 or β4 subunit [29], whereas the scorpion toxins iberiotoxin 
and charybdotoxin (ChTX) fail to inhibit KCa1.1 in the presence of the β4 subunit 
[21]. In addition, the β1, β2, and β4 subunits modulate membrane translocation of 
the KCa1.1-conducting α subunit [23, 24, 30]. To date, however, no KCa1.1 β 
subunit has been described in RA-FLS. Our aims in this study were to determine 
whether RA-FLS express any accessory β subunits and whether expression of these 
subunits varies with the invasive potential of these cells. 
Methods 
Ethical considerations 
FLS were collected and banked for research in a deidentified manner by the 
Feinstein Institute for Medical Research Tissue Donation Program (Manhasset, 
NY, USA) under the approval of the institutional review board (IRB) of the 
Feinstein Institute for Medical Research. All patients provided written consent to 
have their tissues, RNA, DNA, and cells studied. The consent forms are held by the 
Feinstein Institute Tissue Donation Program; the authors of this study had access 
only to cells and deidentified data. The IRB at Baylor College of Medicine has 
established that the work conducted there did not constitute human research, since 
the samples were already banked for research and were deidentified, and thus could 
not be traced back to their donors. 
Rat testes were obtained from Prof. Robert M. Bryan’s laboratory (Department of 
Anesthesiology, Baylor College of Medicine, Houston, TX, USA). Rats were killed 
following American Veterinary Medical Association guidelines under an 
institutional animal care and use committee-approved protocol at Baylor College of 
Medicine. Discarded testes from healthy animals were obtained as control samples 
for our studies. 
Cells 
FLS from 14 patients with RA (age 58 ± 10 years) and 4 patients with osteoarthritis 
(OA) (age 57 ± 5 years), defined according to the criteria of the American College 
of Rheumatology [31], were purchased from Asterand Bioscience (Detroit, MI, 
USA) or collected as described elsewhere [32, 33] (Table 1). Cells were used 
between passages 4 and 11 for all experiments. They were cultured in DMEM (Life 
Technologies, Grand Island, NY, USA) supplemented with 10 IU/ml penicillin, 
0.1 g/ml streptomycin, 1 mM sodium pyruvate, 2 mg/ml L-glutamine, and 10 % 
FBS. 
Table 1 
Characteristics of the subjects who donated fibroblast-like synoviocytes for this 
study 
Donor Diagnosis Sex Ethnicity 
Disease 
duration 
(years) 
RF Medications 
Origin of 
cells 
Figures 
showing 
which cells 
were useda 
RA-1 RA Female White 3 + NSAID 
Asterand 
Bioscience 
1a, b; 2a, b; 
3a, b, d 
RA-2 RA Male Hispanic <1 + Prednisone, DMARD 
Asterand 
Bioscience 
2a, b; 5a, b, c; 
6b 
RA-3 RA Female White <1 + NSAID 
Asterand 
Bioscience 
2a, b; 3a, b, d 
RA-4 RA Female White 12 + NSAID, prednisone 
Asterand 
Bioscience 
1a, b; 2a, b; 
4c 
RA-5 RA Female Hispanic 2 + DMARD, NSAID FITDP 
1a, b; 4a, b, e, 
f, g; 5a, b, c 
RA-6 RA Female White 21 + Prednisone, DMARD FITDP 3a, b, c, d 
RA-7 RA Female White 30 + Prednisone, DMARD FITDP 
2a, b; 3a, b, c, 
d; 4c, d, e, f 
RA-8 RA Female White 20 + Etanercept, prednisone FITDP 1a, b; 2a, b 
Donor Diagnosis Sex Ethnicity 
Disease 
duration 
(years) 
RF Medications 
Origin of 
cells 
Figures 
showing 
which cells 
were useda 
RA-9 RA Female White 21 + 
Leflunomide, 
etanercept, prednisone 
FITDP 
1a, b; 4a, b; 
5a, b, c; 6a, b 
RA-10 RA Male White 15 + 
NSAID, prednisone, 
adalimumab 
FITDP 
2a, b; 3c; 4c, 
d, e, f, g 
RA-11 RA Female 
African 
American 
11 + 
Hydroxychloroquine, 
prednisone 
FITDP 
2a, b; 3c; 4c, 
d, e, f, g 
RA-12 RA Male White >10 + Etanercept FITDP 
1a, b; 3c; 4a, 
b 
RA-13 RA Female Hispanic >10 + 
Methotrexate, 
prednisone 
FITDP 
3a, b, c, d; 4c, 
d, e, f; 6a, b 
RA-14 RA Female White 3 + 
Prednisone, 
methotrexate 
FITDP 5a, b, c; 6a, b 
OA-1 OA Female White 12 − None 
Asterand 
Bioscience 
4c, d, e, f 
OA-2 OA Male White 16 − None 
Asterand 
Bioscience 
4c, d, e, f 
OA-3 OA Male White 25 N/A None FITDP 4c, d, e, f 
OA-4 OA Male White 78 N/A None FITDP 4c, d, e, f 
DMARD disease-modifying antirheumatic drug, FITDP Feinstein Institute Tissue 
Donation Program, N/A not available, NSAIDnon-steroidal anti-inflammatory 
drug, OA osteoarthritis, RA rheumatoid arthritis, RF rheumatoid factor 
Patients with RA were 58 ± 10 years old, and patients with OA were 57 ± 5 years 
old 
aCross-references to figures in this article displaying which cells were used 
Quantitative reverse transcription-polymerase chain reactions 
Total RNA, isolated from cell pellets using TRIzol reagent (Life Technologies), 
was reverse-transcribed with SuperScript III reverse transcriptase and random 
hexamer primers (Life Technologies) according to the manufacturer’s instructions. 
The resulting complementary DNA (cDNA) was used as a template for quantitative 
polymerase chain reaction (qPCR) primers (Table 2), which were designed from 
the National Institutes of Health qPrimerDepot (http://primerdepot.nci.nih.gov/) or 
designed manually and tested by PrimerBlast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Amplicon sizes were between 
70 and 250 bp. qPCRs were conducted in final volumes of 10 μl diluted cDNA 
(1:10) containing 4 μl of oligo forward and reverse primers (2.5 μM each) and 6 μl 
of iTAQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). 
Reactions were run in a ViiA™ 7 Real-Time PCR System (Life Technologies). The 
cycling condition were 20 seconds at 95 °C, 40 cycles at 95 °C for 1 second and 
60 °C for 20 seconds, 95 °C for 15 seconds, 60 °C for 1 minute, and a gradient 
from 60 °C to 95 °C for 15 minutes. The results were analyzed using ViiA™ 7 
software. 
Table 2 
Primers used for quantitative polymerase chain reactions 
Subunit Accession number Sense (forward) 5′-3′ Antisense (reverse) 3′-5′ Base pair 
α NM_002247 GCTCAAGTACCTGTGGACCG CTGGTTTGAGAGTGCCATCC 104 
β1 NM_004137 CTGTACCACACGGAGGACAC GCTCTGACCTTCTCCACGTC 107 
β2a NM_181361 ATTAAGCGTGGCTTTTGAGG GTTGGTCCAGGGTCTCCTTT 98 
β2b NM_005832 GAGAAAGAGCAACAAAGCGG TTAGCAAATCCCAGACATTGC 107 
β3a NM_171828 AAATCACACTTCAGGGCAGC GCACATCTAGTGGGTCTCCA 105 
β3b NM_171829 TCTGAGTGTGAGGGGCTCTT GCACATCTAGTGGGTCTCCA 105 
β3c NM_171830 CCATGATGGGCTTCTCAGTC GCAGTGCAGGTCGATTCTTC 100 
β3d NM_014407 AGGGACGTGCAATATCCCTG GAAAGGCTGTCCTGTGTCTCGT 351 
β3e NM_001163677 ACCCGTGTCTTCAGGTGTTT TCTGTAACATCACGCTTGGGA 107 
β4 NM_014505 CTGAGTCCAACTCTAGGGCG GATTTTCTCTCTTACAGGGAGGG 96 
GAPDH NM_002046 AAGGTGAAGGTCGGAGTCAA AATGAAGGGGTCATTGATGG 108 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
Western blotting 
RA-FLS and a rat testis were lysed in radioimmunoprecipitation assay buffer 
(Sigma-Aldrich, St. Louis, MO, USA) containing 1 % protease inhibitors. Protein 
levels were measured using the Bradford assay. Equal amounts of protein (20 μg) 
were loaded and separated by SDS-PAGE (Life Technologies), then transferred 
onto nitrocellulose membranes (Bio-Rad Laboratories) according to the 
manufacturer’s instructions. Blots were incubated in overnight blocking solution 
consisting of 4 % Blotto nonfat milk (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). Blots were probed using antibodies specific for the human KCa1.1 channel 
α and β subunits (Table 3). Each primary antibody was diluted 1:500 in blocking 
solution. As loading controls, we used antiactin antibodies. Overnight incubation 
and washing were followed by a 2-h probing with IR-680- or IR-800-labeled 
secondary antibodies (Table 3) for 1 h at room temperature. The membranes were 
washed three times for 15 minutes with PBS + 0.1 % Tween 20. Visualization was 
performed with a LI-COR Odyssey Scanner (LI-COR Biosciences, Lincoln, NE, 
USA), and data were analyzed with ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). 
Table 3 
Characteristics of the antibodies used for this study 
Target Host 
Vendor (catalog number; manufacturer 
location) 
Conjugation Clone Use 
Primary antibodies 
 Actin Rabbit Sigma-Aldrich (A2066; St. Louis, MO, USA) – – WB 
 Actin Mouse Sigma-Aldrich (A3853) – AC-40 WB 
 Cadherin-11 Mouse 
Thermo Fisher Scientific (MA1-06306; Rockford, 
IL, USA) 
– 16A FC 
 CD44 Mouse Abcam (ab187571; Cambridge, MA, USA) 
Alexa Fluor 
488 
MEM85 
FC, 
EP 
 KCa1.1α Mouse 
Antibodies, Inc. (NeuroMab, 75-022; UC 
Davis/NIH NeuroMab Facility, Davis, CA, USA) 
– L6/60 WB 
 KCa1.1α Rabbit EMD Millipore (AB5228; Billerica, MA, USA) – – FC 
 KCa1.1β1 Rabbit 
Novus Biologicals (NBP1-33484; Littleton, CO, 
USA) 
– – WB 
 KCa1.1β2 Mouse 
Antibodies, Inc. (NeuroMab, 75-087; UC 
Davis/NIH NeuroMab Facility) 
– N53/32 WB 
 KCa1.1 pan-
β3 
Rabbit Abcam (ab137041) – EPR9543(B) WB 
 KCa1.1 β3a, 
βc, βd, βe 
Mouse 
Rockland Immunochemicals (200-301-E96; 
Limerick, PA, USA) 
– S40B-18 WB 
 KCa1.1β4 Mouse 
Antibodies, Inc. (NeuroMab, 75-086; UC 
Davis/NIH NeuroMab Facility) 
– L18A/3 WB 
 MMP-2 Mouse BioLegend (634802; San Diego, CA, USA) – F14P4D3 FC 
 Podoplanin Rat BioLegend (337003) Phycoerythrin NC-08 FC 
Secondary antibodies 
 Mouse IgG Goat LI-COR Biosciences (926-32210; Lincoln, NE, Infrared-800 – WB 
Target Host 
Vendor (catalog number; manufacturer 
location) 
Conjugation Clone Use 
USA) 
 Mouse IgG1 Goat Thermo Fisher Scientific (A-21127) 
Alexa Fluor 
555 
– FC 
 Rabbit IgG Donkey LI-COR Biosciences (926-68023) Infrared-680 – WB 
 Rabbit IgG Goat Abcam (ab150079) 
Alexa Fluor 
647 
– FC 
EP electrophysiology, FC flow cytometry, IgG immunoglobulin G, KCa calcium-
activated potassium channel, MMP matrix metalloproteinase, WB Western blot 
analysis 
Electrophysiology 
Cells were plated on glass coverslips and allowed to adhere. When indicated, cells 
were incubated for 15 minutes at room temperature with fluorophore-conjugated 
anti-CD44 antibodies (Table 3) and washed, and CD44high and CD44low cells were 
immediately assessed for K+ currents [34]. Total K+ currents were recorded using 
the patch-clamp technique in the whole-cell configuration as described previously 
[11, 12, 35]. The internal solution contained 10 mM ethylene glycol tetraacetic 
acid, 5 mM HEPES, and 5 μM free Ca2+, calculated using Maxchelator 
(http://maxchelator.stanford.edu/CaEGTA-TS.htm). The external solution 
contained 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 10 mM 
HEPES, pH 7.4. Experiments were performed at room temperature (20–22 °C). 
FLS cell capacitances ranged from 9 to 17 pF. Results were analyzed using IGOR 
Pro software (WaveMetrics, Lake Oswego, OR, USA). 
Ion channel modulators 
LCA enhances KCa1.1 currents only when the channel contains the β1 subunit 
[28, 36, 37]. A stock of LCA (Sigma-Aldrich) was prepared in 1:10 solution of 
dimethyl sulfoxide (DMSO) and 70 % ethanol. AA enhances KCa1.1 currents only 
when the channel contains β2 or β3 subunits [29, 36]. A stock of AA (Sigma-
Aldrich) was prepared in DMSO. Paxilline blocks KCa1.1 channels, regardless of β 
subunit expression [11, 14, 38]. A stock of paxilline (Fermentek, Jerusalem, Israel) 
was prepared in DMSO. ChTX blocks all KCa1.1 channels, unless they contain the 
β4 subunit [21, 36, 39]. A stock of ChTX (Peptides International, Louisville, KY, 
USA) was prepared in P6N buffer (10 mM NaHPO4, 0.8 % NaCl, 0.05 % Tween 
20, pH 6.0) [40, 41, 42]. The stock solutions were further diluted with 
electrophysiology bath solution immediately before use so that final DMSO 
concentrations did not exceed 0.05 %. 
Flow cytometry 
Detection of the α subunit of KCa1.1 and of CD44, podoplanin, cadherin 11, and 
intracellular matrix metalloproteinase (MMP)-2 was performed as previously 
described [12, 41, 43] using antibodies listed in Table 3. Cells were treated with 
brefeldin A (eBioscience, San Diego, CA, USA) for 6 h before detection of 
intracellular MMP-2. They were fixed and permeabilized with 0.5 % saponin for 
detection of intracellular epitopes. Data were acquired on a BD FACSCanto II flow 
cytometer (BD Biosciences, San Jose, CA, USA) using BD FACSDiva software 
and analyzed using FlowJo software (Treestar, Ashland, OR, USA). Alternatively, 
live CD44high and CD44low cells were sorted under sterile conditions using a 
FACSAria II flow cytometer (BD Biosciences) and immediately used for invasion 
assays. 
Small interfering RNA transfection 
RA-FLS were kept in serum-free medium for 24 h before small interfering RNA 
(siRNA) treatment with DharmaFECT siRNA transfection reagent and siRNA 
against GAPDH, KCNMB1, or KCNMB3 (GE Dharmacon, Lafayette, CO) as 
described previously [12]. Cells were used 40–80 h later. 
Invasion assays 
The ex vivo invasiveness of FLS was assayed in a transwell system using collagen-
rich, Matrigel-coated inserts (BD Biosciences) as described elsewhere [11, 12, 44]. 
Statistical analysis 
We performed nonparametric one-way analysis of variance (Kruskal-Wallis test) to 
calculate the statistical significance of our results, followed by Dunn’s post hoc test 
(Prism software; GraphPad Software, La Jolla, CA, USA). p values less than 0.05 
were considered significant. 
Results 
RA-FLS express multiple β subunits at the messenger RNA and protein levels 
Analysis of messenger RNA (mRNA) levels by quantitative reverse transcription-
PCR (qRT-PCR) in RA-FLS showed expression of most KCa1.1 β subunits 
(Fig. 1a), although the β2b and β3d subunits were barely detectable. When 
compared with the expression levels of the KCa1.1 pore-forming α subunit, the 
highest relative mRNA expression levels were found for three splice variants of the 
β3 subunit (β3b, β3c, and β3e) and for β4 subunits (Fig. 1b). Since mRNAs are not 
always translated into proteins, we used Western blotting to determine protein 
levels of the different β subunits. Analysis of the total cellular protein content 
showed variable amounts of all β subunits of KCa1.1 in different RA-FLS donors 
compared with the loading control actin. Whereas expression of β1, β2, and β4 was 
only detectable in the cell lysates from some donors, β3 subunits were consistently 
identified in all RA-FLS donors but one (Fig. 2). 
 Fig. 1 
Fibroblast-like synoviocytes from patients with rheumatoid arthritis express 
messenger RNA of multiple KCa1.1 β subunits. a expression fold measurements 
were conducted by quantitative reverse transcription polymerase chain reaction, 
compared with GAPDH expression (n = 6 donors with 3 independent repeats). Each 
bar shows expression of a different KCa1.1 subunit, the letters a–-e represent 
different transcript variants. b α/β ratio showing the amount of KCa1.1 α subunits 
expressed for each single β subunit. Note the different scales of the y-
axis. ΔcT comparative cycle threshold, GAPDH glyceraldehyde 3-phosphate 
dehydrogenase 
 Fig. 2 
Fibroblast-like synoviocytes from patients with rheumatoid arthritis (RA-FLS) 
express proteins of multiple calcium-activated potassium channel KCa1.1 β 
subunits. a Representative Western blot from a gel loaded with proteins from one 
RA-FLS donor with different lanes probed with antibodies against different 
subunits of KCa1.1 (top) and actin (bottom). b Intensity of KCa1.1 α and β subunit 
protein bands normalized to actin expression levels in RA-FLS. Each symbol on 
the scatterplot represents results from a different donor. The horizontal 
bar represents the mean for each subunit 
RA-FLS express either β1 or β3b subunits at their plasma membrane 
The pore-forming α subunits of KCa1.1 can be detected at the plasma membrane 
and in the nucleus of RA-FLS [11]. Since our focus was on the channels expressed 
at the plasma membrane of FLS, and since coexpression of β subunits with α 
subunits affects the kinetics and pharmacology of K+ currents through the KCa1.1 
channel, we used patch-clamp electrophysiology to assess the expression of 
functional β subunits at the plasma membrane of RA-FLS. Of the 51 cells from 5 
different RA-FLS donors patch-clamped, 47 (92 %) exhibited a K+ current 
(Fig. 3a), as previously described [11]. Addition of paxilline, a blocker of the 
KCa1.1 α subunits regardless of β subunit expression [11, 14, 38], completely 
blocked the K+ current in all 14 cells tested (Fig. 3a, b), further confirming that the 
K+ channel observed was KCa1.1, as previously demonstrated [11]. The current 
displayed little or no inactivation in any of the cells tested (Fig. 3a). Since β2a, β3a, 
β3c, and β3e subunits have all been shown to induce partial or total inactivation of 
KCa1.1 [36, 39, 45, 46, 47], the lack of inactivation shows that these subunits are 
not involved in the KCa1.1 channel in RA-FLS. 
 Fig. 3 
Functional KCa1.1 β3b subunits are present on the plasma membrane of fibroblast-
like synoviocytes from patients with rheumatoid arthritis (RA-
FLS). a Representative traces of whole-cell KCa1.1 currents elicited by 140-mV 
pulses for 200 milliseconds with 5 μM Ca2+ in the internal solution before (control) 
and after applying 2 μM paxilline (Pax), 100 nM charybdotoxin (ChTX), 30 μM 
arachidonic acid (AA), or 75 μM lithocholic acid (LCA). The two top traces are 
representative of ≥92 % of cells tested; the two middle traces are representative of 
approximately 70 % of cells tested; and the two bottom traces are representative of 
the other approximately 30 % of cells tested. b Peak KCa1.1 currents after different 
treatments normalized to the control levels. Mean ± SEM; n = 5 different 
donors. c Representative Western blot from a gel loaded with proteins from one 
RA-FLS donor or a rat testis extract. Different lanes were probed with antibodies 
against all splice variants of KCa1.1 β3 (pan-β3) or against KCa1.1 β3a, βc, βd, and 
βe only (top), and intensity of KCa1.1 β3 protein bands was normalized to actin 
expression levels in RA-FLS. Mean ± SEM; n = 6 different donors. d Activation 
kinetics (τAct) of RA-FLS K+ currents. Each symbol on the scatterplot represents a 
different cell. n = 5 different donors; **p ≤ 0.01, ***p ≤ 0.001 
To further identify the β subunits associated with the KCa1.1 channels in RA-FLS, 
we used KCa1.1 openers and blockers known to exert different effects on the 
channel, depending on its β subunit composition. We first tested the effects of the 
scorpion venom toxin ChTX on RA-FLS K+ currents, as ChTX can block only 
KCa1.1 channels that do not contain the β4 subunit [21, 36, 39]. ChTX inhibited 
the currents in all cells tested (Fig. 3a, b), demonstrating the absence of β4 subunits 
in KCa1.1 channels of RA-FLS. We next tested the effects of LCA, known to 
enhance currents through KCa1.1 channels only in the presence of β1 subunits 
[28, 36, 37]. An LCA-induced increase in current was observed in only 36 % of 
RA-FLS cells tested (Fig. 3a, b), demonstrating that KCa1.1 channels are formed of 
α and β1 subunits in approximately one-third of the cells. To identify the β subunit 
in the remainder of the RA-FLS, we used AA, known to open KCa1.1 channels and 
thus increase K+ currents in the presence of β2 and β3 subunits, but not β1 or β4 
subunits [29, 36]. Such an increase was observed in 65 % of cells tested (Fig. 3a, 
b). Since the kinetics data above had already eliminated the possibility of β2a, β3a, 
β3c, or β3e subunits (Fig. 3a), this result with AA suggests that the majority of RA-
FLS cells express a β3 subunit, either β3b or β3d. To discriminate between these 
two splice variants of β3, we performed Western blot experiments using two anti-
β3 antibodies. The first antibody is directed to a conserved region of the β3 subunit, 
common to all five splice variants, and leads to a band of the correct molecular 
weight (Figs. 2, 3c). The second antibody used was raised against the N-terminus of 
β3 and therefore detects all splice variants of β3 other than β3b. Although this 
antibody detected a band of the correct molecular weight (about 32 kDa) in rat 
testis extracts, the only tissue with known β3 expression [26], it yielded no 
detectable band with RA-FLS extracts (Fig. 3c), suggesting that RA-FLS express 
the β3b subunit of KCa1.1. Since β1 but not β3b subunits slow the activation 
kinetics (τAct) of KCa1.1 channels [48], we measured these kinetics in RA-FLS and 
found a spread in τAct with only 17 (31 %) of the 54 cells assessed having a 
τAct longer than 4 milliseconds and 69 % of cells having a τAct less than or equal to 4 
milliseconds (Fig. 3d). These results reinforce the finding that different individual 
RA-FLS cells within a line express different β subunits. 
Expression of KCa1.1β3b is associated with higher levels of KCa1.1α and 
CD44 
Since invasiveness is an important feature of aggressive FLS during RA, we 
wanted to test whether invasiveness is associated with a differential expression of 
KCa1.1 β subunits by the cells. In the absence of antibodies that recognize an 
extracellular epitope of either β1 or β3 subunits, we searched for a surrogate marker 
with an extracellular epitope to allow for isolation of live cells. Elevated expression 
of CD44, a type I transmembrane glycoprotein that binds hyaluronan and other 
extracellular and cell surface ligands, by FLS and other cells was observed in RA 
[49, 50]. Interestingly, elevated CD44 expression is associated with enhanced 
invasiveness of cancer cells [51, 52]. To determine whether expression of β1 or β3 
subunits is associated with CD44 expression levels and invasiveness in RA-FLS, 
we first showed an association between elevated expression of KCa1.1α and of 
CD44 (Fig. 4a). We next used flow cytometry to sort CD44high and CD44low RA-FLS 
and performed invasion assays. CD44high RA-FLS were significantly more invasive 
than CD44low cells (Fig. 4b). Since FLS invasiveness has also been associated with 
expression of podoplanin, cadherin-11, and MMP-2 [53, 54], we assessed 
expression levels of these three markers within the CD44lowand CD44high populations 
of RA-FLS. We observed an association between elevated expression of CD44 and 
all three markers (Fig. 4c). We then stained cells for expression of CD44 and 
performed whole-cell patch-clamping to assess K+ current densities and τAct in 
CD44high and CD44low cells (Fig. 4d). CD44high cells exhibited higher current densities 
and faster activation rates than did CD44low cells, suggesting expression of β1 
subunits by CD44low cells and of β3b subunits by CD44high cells (Fig. 4e, f). These 
results were further confirmed by assessing the effects of AA and LCA on the two 
cell subsets, as CD44high cells displayed sensitivity to AA but not LCA, whereas 
CD44low cells displayed sensitivity to LCA and not AA (Fig. 4g). As a control, we 
used minimally invasive FLS obtained from patients with OA [55]. OA-FLS 
exhibited low current densities at 140 mV, fast τAct, and sensitivity to LCA but not 
to AA, similar to CD44low RA-FLS (Fig. 4e–g). 
 Fig. 4 
The calcium-activated potassium channel KCa1.1 β3 subunit is expressed by 
CD44high fibroblast-like synoviocytes from patients with rheumatoid arthritis (RA-
FLS), whereas the β1 subunit is expressed by CD44low RA-FLS and fibroblast-like 
synoviocytes from patients with osteoarthritis (OA-FLS). a Representative flow 
cytometry histograms showing expression of KCa1.1α by CD44high and CD44low RA-
FLS. Gray shading represents control staining; black lines represent CD44 (left) or 
KCa1.1α (middle and right) staining. b Invasiveness of unsorted RA-FLS and RA-
FLS from the same donors sorted by flow cytometry into CD44low and 
CD44high populations. Mean ± SEM; n = 3 RA-FLS donors. The line for the error bar 
for the control was thickened compared with other plots to make it 
visible. c Representative flow cytometry histograms showing expression of 
podoplanin, cadherin-11, and matrix metalloproteinase (MMP)-2 by 
CD44high (green) and CD44low (gray) RA-FLS. In the left panel, gray shading 
represents control staining and black lines represent CD44 staining. d Individual 
RA-FLS stained for CD44. The patch-clamp pipette’s shadow is visible on the right 
of each image. e K+ current density elicited at 140 mV in CD44high RA-FLS, 
CD44low RA-FLS, and OA-FLS. Mean ± SEM; n = 5 RA-FLS donors and 4 OA-FLS 
donors. f Activation kinetics (τAct) of K+ currents elicited at 140 mV in CD44high RA-
FLS, CD44low RA-FLS, and OA-FLS. Mean ± SEM; n = 5 RA-FLS donors and 4 
OA-FLS donors. g K+ current density after treatment of CD44high RA-FLS, 
CD44low RA-FLS, and OA-FLS with 75 μM lithocholic acid (LCA) or 30 μM 
arachidonic acid (AA) and normalized to current densities before treatment 
(horizontal dashed line). Mean ± SEM; n = 5 RA-FLS donors and 4 OA-FLS 
donors. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
Knocking down the β3 subunit of KCa1.1 decreases cell surface expression of 
the pore-forming α subunit of KCa1.1 
We used a pool of siRNA to selectively inhibit gene expression of the β3 subunit. 
In whole-cell patch-clamp assays, RA-FLS became less sensitive to treatment with 
the β3 opener AA after transfection with β3, but not control siRNA, demonstrating 
the effectiveness of the siRNA. Neither control nor β3 siRNA affected the cells’ 
response to LCA, showing a lack of effect on β1 subunits (Fig. 5a). Flow cytometry 
measurements showed that β3 silencing induced a 20 % reduction in expression of 
the KCa1.1 α subunit (Fig. 5b). Moreover, whole-cell KCa1.1 current densities at 
voltages above 50 mV were significantly decreased after KCa1.1 β3 subunit 
silencing (Fig. 5c), suggesting lower surface expression of the pore-forming α 
subunit of KCa1.1. 
 Fig. 5 
Silencing KCa1.1 β3 expression reduces cell surface expression of 
KCa1.1α. a K+ current density of untransfected fibroblast-like synoviocytes from 
patients with rheumatoid arthritis (RA-FLS) and RA-FLS transfected with control 
small interfering RNA (siRNA) or with siRNA against KCa1.1 β3 before (black) 
and after treatment with 30 μM arachidonic acid (AA) (white; top plot) or 75 μM 
lithocholic acid (LCA) (gray; bottom plot) and normalized to current densities 
before treatment. Mean ± SEM; n = 4 RA-FLS donors. b Representative flow 
cytometry histograms showing background staining (gray shading), expression 
levels of KCa1.1α in untransfected RA-FLS (dashed line) and RA-FLS transfected 
with siRNA against KCa1.1β3 (solid black line; left histogram) or with control 
siRNA (solid black line; right histogram). The bar graph below shows the 
percentage of cells expressing KCa1.1α calculated from the flow cytometric 
profiles of three RA-FLS samples. Mean ± SEM. c K+ current densities of RA-FLS 
transfected with control siRNA (open boxes) or with siRNA against KCa1.1β3 
(closed circles) and pulsed stepwise from −40 to 140 mV in 20-mV increments. 
Mean ± SEM; n = 4 RA-FLS donors. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
Knocking down the β3, but not the β1, subunit of KCa1.1 attenuates the ex 
vivo invasiveness of RA-FLS 
Reducing the expression or function of the α subunit of KCa1.1 inhibits the 
invasiveness of FLS [11, 12]. We therefore assessed the effects of silencing the β3 
subunit of KCa1.1 on RA-FLS invasiveness using Matrigel invasion assays. We 
also used a pool of siRNA to inhibit the expression of the β1 subunit of KCa1.1 and 
used the channel’s sensitivity to LCA to demonstrate the effectiveness of the 
siRNA, as control siRNA did not affect the RA-FLS response to LCA, whereas β1 
siRNA reduced it (Fig. 6a). Whereas β3 siRNA reduced the invasiveness of RA-
FLS, silencing the β1 subunit of KCa1.1 did not affect this invasiveness (Fig. 6b). 
 
Fig. 6 
Silencing calcium-activated potassium channel KCa1.1β3 but not KCa1.1β1 
expression reduces inhibits the invasiveness of fibroblast-like synoviocytes from 
patients with rheumatoid arthritis (RA-FLS). a K+ current density of untransfected 
RA-FLS and RA-FLS transfected with control small interfering RNA (siRNA) or 
with siRNA against KCa1.1 β1 before (black) and after treatment with 75 μM 
lithocholic acid (gray) and normalized to current densities before treatment. 
Mean ± SEM; n = 3 RA-FLS donors. b Invasiveness of untransfected RA-FLS and 
RA-FLS transfected with control siRNA, with siRNA against KCa1.1 β3, or with 
siRNA against KCa1.1 β1. Mean ± SEM; n = 4 RA-FLS donors. *p ≤ 0.5, 
**p ≤ 0.01, ***p ≤ 0.001 
Discussion 
The KCa1.1 channel has been proposed as a therapeutic target in the treatment of 
RA [11, 12]. However, the wide tissue distribution of the pore-forming α subunit of 
the channel precludes the use of blockers targeted to this subunit alone, owing to 
the risk of severe side effects in multiple organ systems [16, 17, 18]. KCa1.1 does, 
however, remain an attractive target for therapy because the regulatory β subunits 
of KCa1.1 have restricted tissue distribution [20, 22]. In the present study, we 
demonstrated that RA-FLS express functional β1 and β3 subunits of KCa1.1 at 
their plasma membrane and that expression of β3 is higher on CD44high RA-FLS and 
is associated with a higher expression level of KCa1.1α. Silencing β3, but not β1, 
significantly reduced the invasiveness of RA-FLS. In addition, silencing β3 
reduced the expression level of KCa1.1α. 
Analysis by qRT-PCR showed expression of most β subunits in RA-FLS at the 
mRNA level. Low mRNA expression levels of β accessory subunits have been 
described in the majority of tissues; therefore, it was not surprising to find similar 
results in RA-FLS [26]. In addition, mRNAs are not always translated into proteins, 
requiring the detection of the proteins themselves. In Western blotting experiments, 
we detected β3 subunits in all samples analyzed; however, other β subunits were 
also detectable at the mRNA and protein levels in some samples. Determination of 
the kinetics and pharmacological profile of KCa1.1 currents of RA-FLS by single-
cell electrophysiology demonstrated the expression of functional β1 and β3 
subunits at the plasma membrane. Previous work has also shown the expression of 
the α subunit of KCa1.1 in the nucleus of RA-FLS and in several organelles in 
different cell types [56]. This raises the possibility that β subunits of the channel 
may also be expressed by organelles and play a role not yet understood in FLS. 
Levels of the β subunits were lower than those of the α subunit as measured at the 
mRNA and protein levels by qPCR and Western blot analysis, respectively. It is 
therefore likely that each α subunit tetramer is associated with fewer than four β 
subunits. The ratio of β and α subunits required to modify current kinetics and 
pharmacological responses of KCa1.1 channels remains unclear. Our 
electrophysiology results demonstrate that the numbers of β1 or β3 expressed by 
RA-FLS are sufficient to affect the function of the KCa1.1 channels at their plasma 
membrane. 
The majority of RA-FLS had characteristic whole-cell KCa1.1 K+ currents sensitive 
to paxilline, except for approximately 8 % of the cells that displayed no K+ currents 
under the conditions used, confirming our previous study findings [11]. No single 
assay is sufficient to identify the β subunits associated with α subunits to form 
KCa1.1 channels. We therefore used a combination of patch-clamp 
electrophysiology to measure activation and inactivation kinetics of the currents 
and test the effects of well-characterized pharmacological agents and of Western 
blots using antibodies raised against different epitopes of the β3 subunit. When 
examining the pharmacological response to the perfused agents, we used the bile 
acid derivate LCA, which, at concentrations of 50–150 μM acts as a potent 
reversible potentiator of KCa1.1 currents only in the presence of β1 subunits 
[27, 28]. A minority of cells responded to LCA, indicating functional β1 subunit 
expression on some RA-FLS. In contrast, treating the RA-FLS with 30 μM AA, 
known to enhance KCa1.1 currents only in the presence of β2 or β3 subunits [29], 
induced an increase in current amplitude in the majority of the cells. We tested 
ChTX, which blocks KCa1.1 channels associated with β1, β2, and β3, but not β4 
subunits [21], leading to current block in 100 % of the RA-FLS assayed and thus 
demonstrating the absence of β4 subunits as components of KCa1.1 at the plasma 
membrane of these cells. A phenotype of noninactivating KCa1.1 currents blocked 
by both paxilline and ChTX, and potentiated by AA but not by LCA, leads to the 
conclusion that the majority of RA-FLS mainly express functional KCa1.1 α and 
β3 subunits. Western blots using antibodies specific to different β3 epitopes 
indicated that RA-FLS express the β3b isoform. 
Our data show an association between the expression of KCa1.1 channels formed 
of α and β3 subunits, high current densities, and a high expression of CD44, 
previously shown in RA synovial tissues [49, 50], whereas the αβ1 phenotype was 
associated with low expression of CD44 and lower current densities. Since we had 
previously shown increased expression of KCa1.1α in invasive FLS [12], this 
raised the possibility that a differential expression of β subunits could underlie the 
different expression levels of the α subunit of KCa1.1. Indeed, silencing of the β3 
subunit did decrease expression levels of KCa1.1α and reduced the K+current 
densities, suggesting that β3 may participate in the cell surface expression of the 
channel, as has been described in other systems with β1, β2, and β4 [23, 24, 30]. 
To our knowledge, an association between high expression levels of a potassium 
channels and CD44 has not directly been reported. However, CD44 expression has 
long been associated with cancer cell metastasis [52]. More recently, the expression 
of various potassium channels, including KCa1.1, has also been linked to enhanced 
metastatic potential in cancer [57]. Further work needs to be done to determine 
whether CD44 and potassium channels share any signaling pathways leading to 
their concomitant upregulation in highly motile cells and to assess whether their 
expression or function is interdependent in these cells. Additional work is also 
required to determine whether the switch from KCa1.1 β1 to β3b expression in RA-
FLS is a consequence, an initiating event, or an independent event in the 
upregulation of CD44 by these cells. Finally, it will be interesting to establish 
whether KCa1.1 and CD44 play synergistic roles in regulating the invasiveness of 
RA-FLS. 
The work presented here was focused on the regulatory β subunits of KCa1.1. In 
the last few years, γ subunits of KCa1.1 have also been identified in various tissues 
[25, 58]. These subunits are structurally different from β subunits, but, like β 
subunits, they affect the function of the KCa1.1 channels with which they are 
coexpressed. It is possible that FLS express γ subunits of KCa1.1 in addition to the 
β subunits we have identified, either at the plasma membrane or in organelles. 
The KCa1.1 channel formed of α and β3 subunits expressed by RA-FLS represents 
an attractive therapeutic target for RA. The mRNA for β3 is expressed only in very 
low quantity in most tissues, with the highest levels detected in the testis [26]. The 
incidence of RA is higher in women than in men [1, 2, 3]; in the majority of 
patients, there would therefore not be a concern about male reproductive organ 
toxicity. Furthermore, the testes are protected by the blood-testis barrier that 
prevents access by many drugs [59]. It is therefore possible to design KCa1.1 
blockers that cannot cross this barrier. 
In addition to this restricted tissue distribution, the presence of β subunits alters the 
pharmacology of the channel. Indeed, several scorpion venom peptides affect 
KCa1.1 channels differently, depending on the β subunit expressed. ChTX and 
iberiotoxin both block KCa1.1 channels containing β1, β2, and β3 subunits, but not 
β4 subunits, [21, 60]. Martentoxin blocks KCa1.1 formed of αβ4, whereas it opens 
KCa1.1 formed of αβ1 and has yet to be tested on KCa1.1 containing β2 or β3 
subunits [61]. It is therefore conceivable that venom peptides that selectively target 
KCa1.1 αβ3 could be identified or that existing KCa1.1-blocking peptides could be 
engineered to enhance their selectivity for this channel as was done successfully 
with other K+channel-blocking peptides [62, 63, 64]. 
Conclusions 
We provide evidence that the KCa1.1 channels expressed at the plasma membrane 
of human FLS contain regulatory β1 or β3b subunits. Expression of the β3b subunit 
is associated with a highly invasive behavior of FLS and high expression of CD44, 
whereas the β1 subunit is associated with low levels of CD44 and lower 
invasiveness of the cells. These data suggest that a blocker selective for KCa1.1 
channels formed of α and β3b subunits and that cannot cross the blood-testis barrier 
will be attractive for targeting KCa1.1 channels on invasive RA-FLS for the 
treatment of RA. 
Abbreviations 
AA:  
arachidonic acid 
  
cDNA:  
complementary DNA 
  
ChTX:  
charybdotoxin 
ΔcT:  
comparative cycle threshold 
  
DMARD:  
disease-modifying antirheumatic drug 
DMSO:  
dimethyl sulfoxide 
  
EP:  
electrophysiology 
  
FC:  
flow cytometry 
FITDP:  
Feinstein Institute Tissue Donation Program 
  
FLS:  
fibroblast-like synoviocyte(s) 
GAPDH:  
glyceraldehyde 3-phosphate dehydrogenase 
  
IgG:  
immunoglobulin G 
IRB:  
institutional review board 
  
KCa:  
calcium-activated potassium channel 
  
LCA:  
lithocholic acid 
MMP:  
matrix metalloproteinase 
  
mRNA:  
messenger RNA 
  
N/A:  
not available 
NSAID:  
non-steroidal anti-inflammatory drug 
  
OA:  
osteoarthritis 
OA-FLS:  
fibroblast-like synoviocytes from patients with osteoarthritis 
  
RA:  
rheumatoid arthritis 
RA-FLS:  
fibroblast-like synoviocytes from patients with rheumatoid arthritis 
  
RF:  
rheumatoid factor 
RT:  
reverse transcription 
  
siRNA:  
small interfering RNA 
  
τAct :  
activation kinetics 
  
WB:  
Western blot 
Declarations 
Acknowledgements 
This work was supported by funding from the Baylor College of Medicine (to 
C.B.). Z.P. was supported by a fellowship from the Campus Hungary Association. 
M.R.T. was supported in part by National Institutes of Health awards GM088129 
and AI053831. R.H. was supported in part by National Institutes of Health award 
HL007676. The Cytometry and Cell Sorting Core at Baylor College of Medicine is 
supported in part by National Institutes of Health grants RR024574, AI036211, and 
CA125123. 
Open AccessThis article is distributed under the terms of the Creative Commons 
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons license, and indicate if changes were 
made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made 
available in this article, unless otherwise stated. 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
ZP and RBT performed the RNA and protein extractions, the qPCRs, and Western 
blotting. ZP, RH, and CB performed the electrophysiology experiments. ZP, MRT, 
and CB performed the flow cytometry assays. ZP and MRT conducted the invasion 
assays. ZP and MRT performed the assays with siRNAs. TL and PSG maintained 
the FLS and verified their purity. GP provided expertise and critical feedback. ZP 
and CB wrote the manuscript with input from all authors. All authors read and 
approved the final manuscript. 
References 
1. Gregersen PK, Plenge RM, Gulko PS. Genetics of rheumatoid arthritis. In: 
Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis. 2nd ed. New 
York: Oxford University Press; 2006. p. 3–14.Google Scholar 
2. Gulko PS, Winchester RJ. Rheumatoid arthritis. In: Austen KF, Frank MM, 
Atkinson JP, Cantor H, editors. Samter’s immunologic diseases. 6th ed. 
Philadelphia: Lippincott Williams & Wilkins; 2001. p. 427–63.Google Scholar 
3. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of 
rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295–
302.PubMedGoogle Scholar 
4. Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid 
arthritis. Hand Clin. 2011;27(1):11–20.View ArticlePubMedPubMed 
CentralGoogle Scholar 
5. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low 
rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and 
rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 
2013;19:4344–450.View ArticlePubMedPubMed CentralGoogle Scholar 
6. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like 
synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. 
Immunol Rev. 2008;223:252–70.View ArticlePubMedGoogle Scholar 
7. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in 
rheumatoid arthritis. Immunol Rev. 2010;233:233–55.View 
ArticlePubMedPubMed CentralGoogle Scholar 
8. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive 
responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.View 
ArticlePubMedPubMed CentralGoogle Scholar 
9. Laragione T, Brenner M, Mello A, Symons M, Gulko PS. The arthritis severity 
locus Cia5d is a novel genetic regulator of the invasive properties of synovial 
fibroblasts. Arthritis Rheum. 2008;58:2296–306.View ArticlePubMedPubMed 
CentralGoogle Scholar 
10. Tolboom TC, van der Helm-Van Mil AH, Nelissen RG, Breedveld FC, Toes RE, 
Huizinga TW. Invasiveness of fibroblast-like synoviocytes is an individual patient 
characteristic associated with the rate of joint destruction in patients with 
rheumatoid arthritis. Arthritis Rheum. 2005;52:1999–2002.View 
ArticlePubMedGoogle Scholar 
11. Hu X, Laragione T, Sun L, Koshy S, Jones KR, Ismailov II, et al. KCa1.1 
potassium channels regulate key pro-inflammatory and invasive properties of 
fibroblast-like synoviocytes in rheumatoid arthritis. J Biol Chem. 2012;287:4014–
22.View ArticlePubMedPubMed CentralGoogle Scholar 
12. Tanner MR, Hu X, Huq R, Tajhya RB, Sun L, Khan FS, et al. KCa1.1 inhibition 
attenuates fibroblast-like synoviocyte invasiveness and ameliorates rat models of 
rheumatoid arthritis. Arthritis Rheumatol. 2015;67:96–106.View 
ArticlePubMedPubMed CentralGoogle Scholar 
13. Saleem F, Rowe ICM, Shipston MJ. Characterization of BK channel splice variants 
using membrane potential dyes. Br J Pharmacol. 2009;156:143–52.View 
ArticlePubMedPubMed CentralGoogle Scholar 
14. Zhou Y, Lingle CJ. Paxilline inhibits BK channels by an almost exclusively closed-
channel block mechanism. J Gen Physiol. 2014;144:415–40.View 
ArticlePubMedPubMed CentralGoogle Scholar 
15. Sanchez M, McManus OB. Paxilline inhibition of the alpha-subunit of the high-
conductance calcium-activated potassium channel. Neuropharmacology. 
1996;35(7):963–8.View ArticlePubMedGoogle Scholar 
16. Meredith AL, Thorneloe KS, Werner ME, Nelson MT, Aldrich RW. Overactive 
bladder and incontinence in the absence of the BK large conductance Ca2+-activated 
K+ channel. J Biol Chem. 2004;279:36746–52.View ArticlePubMedGoogle 
Scholar 
17. Sausbier M, Arntz C, Bucurenciu I, Zhao H, Zhou XB, Sausbier U, et al. Elevated 
blood pressure linked to primary hyperaldosteronism and impaired vasodilation in 
BK channel-deficient mice. Circulation. 2005;112:60–8.View 
ArticlePubMedGoogle Scholar 
18. Sausbier M, Hu H, Arntz C, Feil S, Kamm S, Adelsberger H, et al. Cerebellar 
ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. 
Proc Natl Acad Sci U S A. 2004;101:9474–8.View ArticlePubMedPubMed 
CentralGoogle Scholar 
19. Contreras GF, Neely A, Alvarez O, Gonzalez C, Latorre R. Modulation of BK 
channel voltage gating by different auxiliary β subunits. Proc Natl Acad Sci U S A. 
2012;109:18991–6.View ArticlePubMedPubMed CentralGoogle Scholar 
20. Brenner R, Jegla TJ, Wickenden A, Liu Y, Aldrich RW. Cloning and functional 
characterization of novel large conductance calcium-activated potassium channel β 
subunits, hKCNMB3 and hKCNMB4. J Biol Chem. 2000;275:6453–61.View 
ArticlePubMedGoogle Scholar 
21. Meera P, Wallner M, Toro L. A neuronal beta subunit (KCNMB4) makes the large 
conductance, voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and 
iberiotoxin. Proc Natl Acad Sci U S A. 2000;97:5562–7.View 
ArticlePubMedPubMed CentralGoogle Scholar 
22. Orio P, Rojas P, Ferreira G, Latorre R. New disguises for an old channel: MaxiK 
channel β-subunits. News Physiol Sci. 2002;17:156–61.PubMedGoogle Scholar 
23. Shruti S, Urban-Ciecko J, Fitzpatrick JA, Brenner R, Bruchez MP, Barth AL. The 
brain-specific β4 subunit downregulates BK channel cell surface expression. PLoS 
One. 2012;7, e33429.View ArticlePubMedPubMed CentralGoogle Scholar 
24. Toro B, Cox N, Wilson RJ, Garrido-Sanabria E, Stefani E, Toro L, et al. KCNMB1 
regulates surface expression of a voltage and Ca2+-activated K+ channel via 
endocytic trafficking signals. Neuroscience. 2006;142:661–9.View 
ArticlePubMedGoogle Scholar 
25. Yan J, Aldrich RW. BK potassium channel modulation by leucine-rich repeat-
containing proteins. Proc Natl Acad Sci U S A. 2012;109:7917–22.View 
ArticlePubMedPubMed CentralGoogle Scholar 
26. Behrens R, Nolting A, Reimann F, Schwarz M, Waldschutz R, Pongs O. 
hKCNMB3 and hKCNMB4, cloning and characterization of two members of the 
large-conductance calcium-activated potassium channel β subunit family. FEBS 
Lett. 2000;474(1):99–106.View ArticlePubMedGoogle Scholar 
27. Bukiya AN, McMillan J, Parrill AL, Dopico AM. Structural determinants of 
monohydroxylated bile acids to activate β1subunit-containing BK channels. J Lipid 
Res. 2008;49(11):2441–51.View ArticlePubMedPubMed CentralGoogle 
Scholar 
28. Bukiya AN, Vaithianathan T, Toro L, Dopico AM. Channel β2-4 subunits fail to 
substitute for β1 in sensitizing BK channels to lithocholate. Biochem Biophys Res 
Commun. 2009;390:995–1000.View ArticlePubMedGoogle Scholar 
29. Sun X, Zhou D, Zhang P, Moczydlowski EG, Haddad GG. β-subunit-dependent 
modulation of hSlo BK current by arachidonic acid. J Neurophysiol. 2007;97:62–
9.View ArticlePubMedGoogle Scholar 
30. Zarei MM, Song M, Wilson RJ, Cox N, Colom LV, Knaus HG, et al. Endocytic 
trafficking signals in KCNMB2 regulate surface expression of a large conductance 
voltage and Ca2+-activated K+ channel. Neuroscience. 2007;147:80–9.View 
ArticlePubMedGoogle Scholar 
31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 
Rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative. 
Arthritis Rheum. 2010;62:2569–81.View ArticlePubMedGoogle Scholar 
32. Chan A, Akhtar M, Brenner M, Zheng Y, Gulko PS, Symons M. The GTPase Rac 
regulates the proliferation and invasion of fibroblast-like synoviocytes from 
rheumatoid arthritis patients. Mol Med. 2007;13:297–304.View 
ArticlePubMedPubMed CentralGoogle Scholar 
33. Laragione T, Gulko PS. mTOR regulates the invasive properties of synovial 
fibroblasts in rheumatoid arthritis. Mol Med. 2010;16:352–8.View 
ArticlePubMedPubMed CentralGoogle Scholar 
34. Wulff H, Calabresi P, Allie R, Yun S, Pennington MW, Beeton C, et al. The 
voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J 
Clin Invest. 2003;111:1703–13.View ArticlePubMedPubMed CentralGoogle 
Scholar 
35. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, et al. 
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 
channels for therapy of autoimmune diseases. Mol Pharmacol. 2005;67:1369–
81.View ArticlePubMedPubMed CentralGoogle Scholar 
36. Torres YP, Granados ST, Latorre R. Pharmacological consequences of the 
coexpression of BK channels α and β subunits. Front Physiol. 2014;5:383.View 
ArticlePubMedPubMed CentralGoogle Scholar 
37. Bukiya AN, Liu J, Toro L, Dopico AM. β1 (KCNMB1) subunits mediate 
lithocholate activation of large-conductance Ca2+-activated K+ channels and dilation 
in small, resistance-size arteries. Mol Pharmacol. 2007;72:359–69.View 
ArticlePubMedGoogle Scholar 
38. Strøbaek D, Christophersen P, Holm NR, Moldt P, Ahring PK, Johansen TE, et al. 
Modulation of the Ca2+-dependent K+channel, hslo, by the substituted diphenylurea 
NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903–
14.View ArticlePubMedGoogle Scholar 
39. Wang B, Jaffe DB, Brenner R. Current understanding of iberiotoxin-resistant BK 
channels in the nervous system. Front Physiol. 2014;5:382.PubMedPubMed 
CentralGoogle Scholar 
40. Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, et al. 
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: 
implications for autoimmune diseases. FASEB J. 2014;28:3952–64.View 
ArticlePubMedPubMed CentralGoogle Scholar 
41. Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, et al. Blocking Kv1.3 
channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol 
Chem. 2014;289:12623–32.View ArticlePubMedPubMed CentralGoogle 
Scholar 
42. Tarcha EJ, Chi V, Munoz-Elias E, Bailey D, Londono LM, Upadhyay SK, et al. 
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 
channel inhibitor that suppresses T cell mediators of autoimmune diseases. J 
Pharmacol Exp Ther. 2012;342:642–53.View ArticlePubMedPubMed 
CentralGoogle Scholar 
43. Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, et al. A novel 
fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in 
chronically activated T lymphocytes. J Biol Chem. 2003;278(11):9928–37.View 
ArticlePubMedGoogle Scholar 
44. Laragione T, Cheng KF, Tanner MR, He M, Beeton C, Al-Abed Y, et al. The 
cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and 
synovial fibroblast invasion. Clin Immunol. 2015;158:183–92.View 
ArticlePubMedGoogle Scholar 
45. Hu S, Labuda MZ, Pandolfo M, Goss GG, McDermid HE, Ali DW. Variants of the 
KCNMB3 regulatory subunit of maxi BK channels affect channel inactivation. 
Physiol Genomics. 2003;15:191–8.View ArticlePubMedGoogle Scholar 
46. Orio P, Latorre R. Differential effects of β1 and β2 subunits on BK channel 
activity. J Gen Physiol. 2005;125:395–411.View ArticlePubMedPubMed 
CentralGoogle Scholar 
47. Wallner M, Meera P, Toro L. Molecular basis of fast inactivation in voltage and 
Ca2+-activated K+ channels: a transmembrane β-subunit homolog. Proc Natl Acad 
Sci U S A. 1999;96(7):4137–42.View ArticlePubMedPubMed CentralGoogle 
Scholar 
48. Lee US, Cui J. β subunit-specific modulations of BK channel function by a 
mutation associated with epilepsy and dyskinesia. J Physiol. 2009;587:1481–
98.View ArticlePubMedPubMed CentralGoogle Scholar 
49. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an 
adhesion molecule as an indicator of inflammatory disease activity: up-regulation 
of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum. 
1991;34:1434–43.View ArticlePubMedGoogle Scholar 
50. Naor D, Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res Ther. 
2003;5:105–15.View ArticlePubMedPubMed CentralGoogle Scholar 
51. Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor 
invasion of connective tissue. Front Biosci. 1998;3:d604–15.View 
ArticlePubMedGoogle Scholar 
52. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis. 2003;20:195–
201.View ArticlePubMedGoogle Scholar 
53. Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner MB. 
Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis 
Rheum. 2009;60(5):1305–10.View ArticlePubMedPubMed CentralGoogle 
Scholar 
54. Ekwall AK, Eisler T, Anderberg C, Jin C, Karlsson N, Brisslert M, et al. The 
tumour-associated glycoprotein podoplanin is expressed in fibroblast-like 
synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. 
Arthritis Res Ther. 2011;13(2):R40.View ArticlePubMedPubMed 
CentralGoogle Scholar 
55. Tolboom TCA, Pieterman E, van der Laan WH, Toes REM, Huidekoper AL, 
Nelissen RGHH, et al. Invasive properties of fibroblast-like synoviocytes: 
correlation with growth characteristics and expression of MMP-1, MMP-3, and 
MMP-10. Ann Rheum Dis. 2002;61:975–80.View ArticlePubMedPubMed 
CentralGoogle Scholar 
56. Singh H, Stefani E, Toro L. Intracellular BKCa (iBKCa) channels. J Physiol. 
2012;590:5937–47.View ArticlePubMedPubMed CentralGoogle Scholar 
57. Comes N, Serrano-Albarrás A, Capera J, Serrano-Novillo C, Condom E, Ramón Y, 
et al. Involvement of potassium channels in the progression of cancer to a more 
malignant phenotype. Biochim Biophys Acta. 1848;2015:2477–92.Google Scholar 
58. Zhang J, Yan J. Regulation of BK channels by auxiliary γ subunits. Front Physiol. 
2014;5:401.PubMedPubMed CentralGoogle Scholar 
59. Quignot N. Modeling bioavailability to organs protected by biological barriers. In 
Silico Pharmacol. 2013;1:8.View ArticlePubMedPubMed CentralGoogle 
Scholar 
60. Candia S, Garcia ML, Latorre R. Mode of action of iberiotoxin, a potent blocker of 
the large conductance Ca2+-activated K+ channel. Biophys J. 1992;63:583–90.View 
ArticlePubMedPubMed CentralGoogle Scholar 
61. Tao J, Shi J, Liu ZR, Ji YH. Martentoxin: a unique ligand of BK channels. Sheng 
Li Xue Bao. 2012;64:355–64.PubMedGoogle Scholar 
62. Beeton C, Pennington MW, Norton RS. Analogs of the sea anemone potassium 
channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy 
Drug Targets. 2011;10:313–21.View ArticlePubMedPubMed CentralGoogle 
Scholar 
63. Beeton C. Targets and therapeutic properties. In: Kastin AJ, editor. Handbook of 
biologically active peptides. 2nd ed. San Diego, CA: Elsevier/Academic Press; 
2013. p. 473–82.View ArticleGoogle Scholar 
64. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, et al. 
Development of a sea anemone toxin as an immunomodulator for therapy of 
autoimmune diseases. Toxicon. 2012;59:529–46.View ArticlePubMedPubMed 
CentralGoogle Scholar 
 
